Author

F. El-Turk

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

A. Talebi· 1 shared C. Goncalves· 1 shared F. Cai· 1 shared F. Huang· 1 shared J. Dehairs· 1 shared J. J. Mitchell· 1 shared J. Su· 1 shared J. V. Swinnen· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Talebi

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Disrupting peroxisomes alters lipid metabolism in melanoma and uncovers a novel therapeutic vulnerability in combination with MAPK-targeted therapies

F. Huang, F. Cai, M. S. Dahabieh, K. Gunawardena, A. Talebi, J. Dehairs, F. El-Turk, J. Y. Park, C. Goncalves, N. Gagnon, J. Su, P. Gaub, J.-S. Joyal, J. J. Mitchell, J. V. Swinnen, , S. V. del Rincon

This paper identifies a metabolic vulnerability in melanoma cells by disrupting peroxisomes and shows that combining this with MAPK-targeted therapies enhances anti-tumor effects.

bioRxiv · Oct 25, 2022 · PreprintCancer Biology